Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL…
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with…
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). The prominent use of generically available drugs (e.g.,…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). The prominent use of generically available drugs (e.g.,…
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. DME…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…